METHUSELAH ARCHIVE INTERVENTIONS / DNP (2,4-DINITROPHENOL) AS A WEIGHT-LOSS DRUG

DNP (2,4-Dinitrophenol) as a weight-loss drug

oral · 1933–2025
category:oral
delivery:Oral capsules or tablets of 2,4-dinitrophenol. In the 1930s: physician-dosed or over-the-counter proprietary tablets, at doses reported in the toxicological literature at around 3 mg/kg. In the modern illicit market: illicitly imported industrial DNP powder, repackaged by online sellers into gelatin capsules (commonly 125mg or 250mg) and shipped worldwide by mail order, disguised under generic 'fat burner' branding.
price tier:not classified
era:1933–2025
current status:historical
regulatory:banned
SHORT PITCH (AS SOLD)
An industrial chemical marketed since 1933 as a metabolism-boosting weight-loss pill; the FDA declared it 'extremely dangerous and not fit for human consumption' in 1938 after an epidemic of cataracts and hyperthermic deaths, yet a 2019 U.S. federal toxicology profile recorded it was 'still marketed for weight loss by unregulated internet sources,' a fatal case was reported in the medical literature in 2024, and a 2025 health-policy review reports UK regulators found DNP in diet pills and prohibited DNP-containing products.
THE ACTUAL EVIDENCE
DNP's core mechanism is real and scientifically uncontroversial: it uncouples mitochondrial oxidative phosphorylation, raising metabolic rate and producing genuine, measurable weight loss. Tainter, Stockton & Cutting first documented that metabolic-rate increase and weight loss clinically (JAMA, 1933); the uncoupling mechanism behind it is established by later toxicology (Grundlingh et al. 2011; ATSDR). That is precisely what makes it lethal rather than merely ineffective. The same mechanism that burns fat also generates uncontrolled body heat once a small threshold is crossed, there is no antidote, and the margin between an active dose and a fatal one is extremely narrow. 1930s case reports documented an epidemic of bilateral cataracts, some progressing to near-blindness, among dieters taking doses within the range physicians recommended (Horner, Archives of Ophthalmology, 1942), alongside hyperthermic deaths; the FDA declared DNP 'extremely dangerous and not fit for human consumption' and discontinued its use as a weight-reduction drug in 1938 (ATSDR Toxicological Profile for Dinitrophenols; Colman, Regulatory Toxicology and Pharmacology, 2007). It never disappeared: modern toxicological review documents a marked resurgence in DNP poisoning and deaths since the early 2000s, driven by unregulated internet sales to bodybuilders and dieters, with the sentencing judge in R v Rebelo recording that 18% of those presenting at hospital between 2007 and 2019 with a history of having taken DNP died and no established treatment beyond aggressive supportive cooling (Grundlingh et al., Journal of Medical Toxicology, 2011). A 2024 peer-reviewed case report confirms the pattern has continued into the current decade (Hermetet et al., Frontiers in Public Health, 2024). No study has ever established a safe human dose.
PRACTITIONERS
INGREDIENTS
CASES
CLAIMS
SOURCES
  1. Use of Dinitrophenol in Obesity and Related Conditions: A Progress Report (1933)
  2. Dinitrophenol and Its Relation to Formation of Cataract (1942)
  3. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma (2007)
  4. Toxicological Profile for Dinitrophenols (2019)
  5. 2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death (2011)
  6. Case report: Fatal long-term intoxication by 2,4-dinitrophenol and anabolic steroids in a young bodybuilder with muscle dysmorphia (2024)
  7. Food Standards Agency issues urgent advice on consumption of 'fat burner' capsules containing DNP (2003)
  8. DNP: the dangerous diet pill pharmacists should know about (2019)
  9. The regulation on the use of supplements for weight control: Case studies from Australia, the United States of America, and the United Kingdom (2025)
  10. R v Bernard Rebelo: Sentencing Remarks of the Hon. Mrs Justice Whipple DBE (2020)
NOTES

2,4-Dinitrophenol is an industrial nitrophenol compound whose capacity to raise the body’s metabolic rate was turned into a weight-loss drug in 1933, following clinical studies by a Stanford pharmacology group. It produced real, measurable weight loss, and by the drug’s first year an estimated 100,000 Americans were taking it. It also produced an epidemic of cataracts and a run of hyperthermic deaths, and in 1938 the newly empowered FDA declared it “extremely dangerous and not fit for human consumption,” ending its legitimate medical use. That should have been the end of the story. Instead, DNP re-emerged decades later as an unregulated internet product marketed to bodybuilders and dieters chasing rapid fat loss, with an 18% fatality rate among those who presented to hospital after taking it between 2007 and 2019 (per the sentencing judge in R v Rebelo, citing the toxicological literature), and no antidote once toxicity begins. A 2019 U.S. federal toxicology profile recorded it was still marketed by unregulated internet sources; a fatal case was reported in 2024; and a 2025 health-policy review reports that UK regulators found DNP in diet pills and prohibited DNP-containing products — the same chemical, under the same basic promise, resurging and drawing renewed regulatory action more than eighty years after regulators first tried to stop it.